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Hepatitis C virus, which usually starts during dialysis therapy, is currently the main cause of chronic liver disease in such
population. The majority of patients acquired the disease through intravenous drug use or blood transfusion, with some risk
factors identiﬁed. In this review we are dealing with the eﬀect of renal transplantation on HCV infection and HCV-related
complications after renal transplantation. Moreover, we are discussing the therapeutic options of HCV infection before and
after renal transplantation, the best immunosuppressive protocol and lastly graft and patient survival in patients who underwent
pretransplant management vs. those who were transplanted without treatment.
1.Introduction
Liver disease is one of the leading causes of death in long-
term renal transplant survivors [1, 2], and hepatitis C virus
(HCV) is currently the main cause of chronic liver disease
in such population [1–7]. Hemodialysis patients represent a
high-riskgroupforHCVinfection,possiblyduetoadirector
indirect exposuretocontaminated blood[6].AlthoughHCV
infection may be transmitted through transplantation itself
[1, 8], it usually starts during dialysis therapy [1–4].
2.HCVGenotypesandPrevalence
Worldwide, at least 6 major genotypes of the HCV have
been identiﬁed, each comprising multiple subtypes [9–13].
G e n o t y p e s1 ,2 ,a n d3h a v eaw o r l dwide distribution, while
their relative prevalence varies from one geographic area to
another. Hepatitis C virus subtypes 1a and 2b are the most
commongenotypesintheUnitedStatesandEurope[14–16].
Subtype 1b is responsible for up to 73% of HCV infection
in Japan [17]. Subtypes 2a and 2b are relatively common
in North America, Europe, and Japan, while 2c is found
commonly in Northern Italy. Intravenous drug abusers in
Europe and the United States have the HCV genotype 3a
[18]. Genotype4 appears to beprevalentin North Africa and
the Middle East while genotypes 5 and 6 in South Africa and
Hong Kong [10–12].
3.Transmission
The majority of HCV infected patients acquired the disease
through intravenous drug use or blood transfusion, with
the following risk factors identiﬁed [13]: intravenous drug
use, blood transfusion, sex with an intravenous drug user,
having been struck or cut with a bloody object, pierced
ears or body parts, and immunoglobulin injection. Other
risk factors identiﬁed among dialysispatients includedblood
transfusions, the duration of end-stage renal disease (and
dialysis), the type of dialysis (risk is the highest with
in-hospital hemodialysis especially with lack of adherence
to universal precautions and the lowest with peritoneal
dialysis), and the prevalence of HCV infection in the dialysis
unit.
4.Diagnostic Approachto
HepatitisCVirusInfection
HCV RNA testing should be performed in those with
a positive antibody test, especially when antiviral treat-
ment is being considered, and in those with unexplained
liver disease and negative anti-HCV test especially who
are immunocompromised or suspected of having acute
HCV infection. HCV genotype should be determined in
all infected persons prior to treatment to determine the
duration of therapy and the likelihood of response [19].2 International Journal of Nephrology
Absence of HCV RNA despite anti-HCV antibodies may
be seen in a number of circumstances especially with
false positive results on antibody tests due to techni-
cal reasons, anti-HCV antibodies that have been pas-
sively acquired from blood transfusions, maternal anti-
HCV antibodies in babies; intermittent viremia, HCV
sequestration at sites other than the blood stream and
the number of copies of HCV RNA below the limit
of detection and in immunocompromised patients [14,
15].
5.EffectofRenalTransplantationon
HCVInfection
Renal transplantation guidelines [5, 6] recommend that
all transplant candidates should be evaluated for HCV
infection; positive anti-HCV antibodies by immunoassay
(EIA) require conﬁrmation by HCV RNA determination.
Most EIA positive patients have detectable HCV RNA in
their sera. This viremic state continues in most of transplant
recipients. Chronic liver disease after renal transplantation
depends on many risk factors such as the pretransplant
duration and the severity of HCV infection, the liver
histopathology, the coinfection with hepatitis B virus, the
duration after transplantation and the type of induction
andmaintenanceimmunosuppression[1–5].However,some
studies [20, 21] showed that antibody induction had
no negative impact on patient survival. The viral load
increases up to 30 times compared to levels before trans-
plantation in HCV RNA-positive patients, suggesting the
role of immunosuppressive regarding this issue [16, 17].
Mycophenolate mofetil [18] and antithymocyte globulin
[1] increase HCV viremia while cyclosporin inhibits the
replication of HCV in cultured hepatocytes [22]. It is worth
mentioning that HCV-RNA titers do not diﬀer between
patients with or without posttransplant liver disease [1]
and are not clearly related to liver disease progression
[23]. Apart from cases with ﬁbrosing cholestatic hepatitis
[24], HCV infection after renal transplantation usually has
ab e n i g nc o u r s e[ 4, 5, 25], with normal transaminases
in 20–51% of cases [4]. In a meta-analysis, cause-speciﬁc
mortality due to liver disease (cirrhosis or hepatocellu-
lar carcinoma (HCC)) in HCV-infected kidney transplant
recipients was increased in most of the studies, with a
RR of death of 1.79, compared to HCV-negative cases
[20].
Liver biopsies in cases with chronic elevation of transam-
inases have documented severe liver disease, for example,
chronic active hepatitis or cirrhosis, in up to 20% of
HCV-positive transplant recipients [4]. Zylberberg et al.
[21] described a faster progression of the liver histological
activity and ﬁbrosis in kidney transplant patients than
in non-immunocompromised patients infected by HCV
although Alric et al. [23] observed a slow progression of
liver ﬁbrosis in HCV-infected kidney transplant patients,
a ﬁnding which was also inferior to that observed in
infected patients with a normal renal function. The use of
diﬀerent immunosuppressive protocols might explain these
discrepancies.
6.TherapeuticOptionsofHCVInfectionand
KidneyTransplantation
The problem of anti-HCV therapy is that interferon (IFN)
has been associated with an increased risk of allograft
rejection not only in the functioning grafts but also in the
already failed grafts [26, 27]. Therefore this may explain
the major hesitancy to the use of IFNa in renal transplant
recipients [12]. It increases rejection possibly by cytokine
gene expression, increased cell surface expression of HLA
antigens, and enhanced function of natural killer cells,
cytotoxic T cells, and monocytes. These immune-stimulant
eﬀectscanresultinenhanced allograft rejection—which may
be irreversible—even in patients with stable grafts [28, 29].
So it has been indicated only in patients with ﬁbrosing
cholestatic hepatitis [3, 30, 31] or other conditions in which
the beneﬁts of treatment outweigh the risk of allograft loss.
There are extremely limited data evaluating the eﬃcacy and
complications of IFNa therapy in the treatment of possible
HCV-related cryoglobulinemia or de novo or recurrent
glomerular disease in renal transplant recipients [28, 29].
Pageaux et al. [32] showed that treatment of HCV with
IFN after transplantation might not be as risky as initially
shown. Posttransplant monotherapies with ribavirin and/or
amantadine have no apparent impact on HCV viremia or
liver histology [30].
So the best strategy is to treat HCV infection in patients
on dialysis before transplantation [2, 3, 6, 7, 33–37]a f t e r
excluding cirrhosis by liver biopsy and if present patients
should be considered for combined kidney-liver transplan-
tation. Such strategy could prevent liver disease progression
[30] and even HCV-related morbidities such as glomeru-
lonephritis [34] and posttransplant diabetes mellitus [29].
IFN-based therapy should be oﬀered to patients with an
active viral infection (HCV RNA positive) and a biopsy-
proven chronic hepatitis. Liu demonstrated the superior
eﬃcacy and safety proﬁle of pegylated-IFN as compared
with standard-IFN on dialysis-treated patients [38]. Using
multivariate analysis, pegylated-IFN was independently pre-
dictive of sustained virological response (SVR). Combined
therapy with pegylated-IFN and low-dose ribavirin achieved
SVR in most of patients enrolled in the study [39], but the
majority of cases (74%) developed severe anemia. Therefore,
the treatment would consist of standard-IFN, 3 million units
three times a week for 48 weeks for genotypes 1 and 4, and
24 weeks for genotypes2 and 3. This treatment achieves SVR
in around 40% of treated patients [26, 40].
7.HCV-RelatedComplicationsafterRenal
Transplantation
7.1. Glomerular Lesions. The most frequent glomerular le-
sionsobservedamongHCV-positivekidneytransplant recip-
ients are cryoglobulinaemic or noncryoglobulinaemic mem-
branoproliferative glomerulonephritis (MPGN) [41, 42]a n d
membranous glomerulonephritis (MGN) [43]. Transplant
glomerulopathy [2], anticardiolipin-related thrombotic
microangiopathy [44], and ﬁbrillary glomerulonephritis
[45] have also been described. The pathogenesis of MPGNInternational Journal of Nephrology 3
and MGN seems to be due to deposition of immune
complexescontaining viral RNAin the glomerulus[2, 46], as
viral antigens have been detected by immunohistochemistry
[47].
HCV-associated glomerulonephritis has been postulated
to be due to abnormality in Toll-like receptor—proteins
expressed on immune and nonimmune cells as impor-
tant components of the innate immunity—because W¨ ornle
et al. [48] found that these receptors were elevated in
the mesangial cells in HCV-related glomerulonephritis and
was associated with enhanced proinﬂammatory cytokines.
Till now there is no speciﬁc therapy for the treatment of
HCV- related glomerular lesions after renal transplantation.
However, rituximab, an anti-CD20 antibody that targets
B cells, has been eﬀective in some cases of HCV-related
posttransplant cryoglobulinemia. P´ erez-Calvo et al. in [49]
had evaluated its safety in HCV-positive patients, and they
concluded that it is a promising treatment modality for
HCV-associated extra-hepatic disorders [49].
7.2. Posttransplant Diabetes Mellitus (PTDM). The diagnosis
of hyperglycemia should be according to current American
Diabetes Association (ADA) criteria (fasting blood glucose
>125mg/100mL on two separate measures). Lastly, patients
with PTDM should be referred to a diabetologist [6]. HCV
infection seems to be related to a higher incidence of
diabetes mellitus [2]. In a meta-analysis of 13 observational
studies including more than 30000 renal transplant patients,
Fabrizi et al. [50] found signiﬁcant increase in the risk
of PTDM in HCV-positive patients. Moreover, tacrolimus
in HCV-infected patients has been described to increase
the incidence of PTDM [50, 51], which may be one
of the risk factors explaining a lower patient and graft
survival among HCV-positive patients [6]. Insulin resistance
caused by inhibitory actions of the virus on hepatic insulin
regulatory pathways [52] in addition to an overexposure to
tacrolimus, especially during the ﬁrst days after transplan-
tation, represented the main mechanisms. Moreover, HCV
replicationprobably slows downtacrolimus metabolism [53,
54]. So optimization of immunosuppressive agents that are
clearly associated with PTDM should be balanced to get
their antirejection eﬃcacy, while minimizing the risk of
hyperglycaemia, as 2008 KDIGO guidelines recommended
[6].
7.3. Acute Rejection. T h ei s s u ew h e t h e rH C Vi n f e c t i o n
d e c r e a s e so re n h a n c e st h er i s ko fa c u t er e j e c t i o ni ss t i l la
controversial. HCV induces a state of immunodeﬁciency,
based on a reduction in the rate of na¨ ıve T-helper lym-
phocytes and an alteration in the proliferative responses
to mitogens of T lymphocytes [55], which might explain
a decreased incidence of acute rejection [1–3]. On the
other hand, a similar [8, 56]o re v e nah i g h e ri n c i d e n c e
of acute rejection was observed in HCV-positive patients
[57], possibly due to longer history of renal disease, previous
transplants, and blood transfusions, which are all risk factors
for HCV infection in kidney transplant recipients. Forman
et al. [57] observed a higher incidence of antibody-mediated
acute rejection in their cohort of HCV-positive patients.
In a Spanish series of 435 kidney transplant cases with
a protocol biopsy performed during the ﬁrst 6 months
after transplantation, they concluded that subclinical acute
rejection with chronic allograft nephropathy and hepatitis C
infection were both independent risk factors for graft loss
[58]. From that study, Ser´ on et al. [59] showed that graft
survival improved during this decade despite worsening of
renal quality (elderly donors) and poorer HLA matching
(higher HLA mismatches). They attributed these ﬁndings to
the decrease of the prevalence of HCV infection (from 29%
to 10%; P<. 0001) and acute rejection (from 39% to 25%;
P<. 0001).
7.4. Posttransplant Tuberculosis. Torres et al. [60]r e p o r t e d
that HCV infection is the most important risk factor for
the development of tuberculosis in renal transplant patients.
Therefore, a careful immunosuppressive regimen should be
selected in these patients. We suggest—in immunologically
low-risk patients—either rapamycin-based or cyclosporine
based protocols to be used without steroids. On the other
hand, it will be diﬃcult to ﬁnd the ideal immunosuppressive
strategy for HCV-positive patients with immunological high
risk.
7.5. Malignancies. After organ transplantation HCV infec-
tion has been added to the well-known risk factors of
posttransplant lymphoproliferative disorders (PTLDs) such
as Epstein-Barr virus, induction and antirejection therapies.
Theoverallprevalenceis(0.8%)inrenaltransplantrecipients
and is signiﬁcantly higher in HCV-positive (3.6%) than in
HCV-negative patients (1.2%) [61]. Moreover, in a study
from Taiwan, PTLD was the second cause of posttransplant
neoplasia in HCV-positive recipients [62]. In the American
Registry including 66169 recipients, the incidence of HCV
infection was higher in myeloma patients, suggesting a
possible association between HCV infection and myeloma
[63].
8.PatientSurvivalafterKidneyTransplantation
among HCVInfected Patients
It is reported that the survival of HCV-positive patients
after renal transplantation is signiﬁcantly better than that
of matched patients who remain on dialysis [10, 64, 65].
However, HCV-positive patients after renal transplantation
have a lower patient and graft survival compared to HCV-
negative patients [5–12, 20, 66, 67]. In the short-term
followup, HCV infection after renal transplantation showed
similar survival as compared to noninfected renal transplant
recipients [52]. But in the majority of long-term studies,
HCV-positive patients have a signiﬁcantly lower survival
than HCV-negative patients [3, 10–12, 20, 66]. abdulkarim
et al. [11] found that 10-year patient survival was signiﬁ-
cantly lower in HCV-positive patients: 65.5% versus 85.3%
(P<. 001). Moreover, the multivariate analysis showed that
among HCV-positive renal transplant cases, biopsy-proven
cirrhosis, age, and duration of transplantation were inde-
pendent risk factors for 10-year patient survival and 21% of
deaths were caused by liver disease in HCV-positive patients.4 International Journal of Nephrology
In a Spanish multicenter study with 488 HCV-positive
cases out of a total population of 3,365 patients transplanted
between 1990 and 1998, they concluded that HCV infection
was an independent risk factor for patient death and
mortality rate due to liver disease was higher than that
in HCV-negative patients (13.85% versus 0.6%; P = .03)
[8] and it was progressively increasing by time (10% at
10 years and 20% at 20 years) [9]. Similar ﬁndings were
concluded in a meta-analysis including other observational
studies by Fabrizi et al. [20]. This was partially related to
an increase in liver-related deaths and the higher frequency
of both hepatic and extrahepatic complications in HCV-
positiveas comparedtoHCV-negative recipients[66].Heavy
immunosuppression, probably, increases the risk of HCV
viral replication after renal transplantation especially with
the use of quadruple therapy with monoclonal or polyclonal
antibodies [1].
On the other hand, Luan et al. [68]r e p o r t e dt h a t
antibody induction did not negatively aﬀect patient survival
with HCV infection. Therefore, all conventional current
immunosuppressive drugs can be used in HCV-positive
patients[6].Itisworthmentioningthatcyclosporineinhibits
HCV viral replication in cultured hepatocytes [69]a n d
this supported clinical ﬁndings that HCV-positive renal
transplant recipients under cyclosporine immunosuppres-
sion showed stabilization and regression of liver ﬁbrosis in
more than 50% of patients [23]. The risk of PTDM is higher
inHCV-positive patientstreated withtacrolimus[51],which
can be minimized by low-dose tacrolimus combined with
MMF, together with an early steroid withdrawal. Notably,
mycophenolate mofetil as part of maintenance immunosup-
pressive regimen was associated with better patient survival
[68]. The inﬂuence of m-TOR inhibitors (sirolimus and
everolimus) on patient survival after renal transplantation is
unknown.
9.Inﬂuenceof HCVInfectiononGraftSurvival
HCV infection did not adversely aﬀect short-term graft
survival [51] but exhibited lower long-term graft survival
compared to HCV-negative patients [8, 10–12, 20, 66].
Several studies showed that HCV infection was an inde-
pendent risk factor for graft loss [7, 9, 11, 12, 20, 66–71].
In a meta-analysis including 6345 patients, the presence
of anti-HCV-positive antibodies was an independent and
signiﬁcant factor for graft failure (RR 1.56, 95% CI 1.35–
1.80, P = .019) in four of the eight studies included in the
analysis. The mechanisms might be due to development of
proteinuria because of chronic allograft nephropathy and/or
HCV-associated glomerulonephritisand PTDM. HCVinfec-
tion is an independent risk factor for proteinuria after
transplantation. Hestin et al. [56] reported that persistent
proteinuria developedmore frequentlyinHCV-positive than
in HCV-negative patients. The probability of proteinuria
increases from 19.5% in the HCV-positive versus 7.5% in
HCV-negative patients at 1 year to 22.9% versus 10.7% at 3
years to 45.1% versus 13.1%, respectively, at 5 years. Cosio
et al. [72] found that the prevalence of HCV antibodies
was signiﬁcantly higher in patients with chronic transplant
glomerulopathy (33% in HCV-positive cases versus 1.9% in
negativecases,resp.,P = .0004)andsotheyextrapolatedthat
HCV may produce endothelial cell lesion leading to trans-
plant glomerulopathy. In another study done in Mansoura,
Egypt by Mahmoud et al. [70] they also found a higher
incidence of proteinuria and chronic rejection in a series
of HCV-positive kidney transplant recipients with HCV
RNA in the serum. Notably, absence of IFN therapy before
transplantation was a signiﬁcant risk factor for chronic
allograft nephropathy. Posttransplant cryoglobulinemic or
noncryoglobulinemic MPGN and MGN associated with
HCV infection contribute to the developmentof graft failure
[41–43]. Type I MPGN has been reported to result in
accelerated loss of the graft [41, 42], while, in MGN, the
clinical course and the development of renal failure seem to
be similar in patients with and without HCV infection [70].
Another issue is the use of kidneys from HCV-positive
donors, a procedure which must not be used in anti-
HCV-negative recipients (HCVRs) [62]. However, its use
into HCVR+ is still a matter of debate [3]. Some authors
consideredthattheapproachwasappropriateastheoutcome
after renal transplantation for such patients was better than
remaining on dialysis [73]. Moreover, mid-term outcome of
these patients was similar to that of HCVR+ transplanted
from HCVD-, in terms of patient and graft survival and
HCV-relatedliverdisease[74].Hence,itcanbeasafestrategy
to overcome organ shortage for transplantation, but long-
term assessment is still needed [6, 7, 75].
10.Conclusions
Hepatitis C virus infection is the most frequent cause of
liver disease after renal transplantation; although it has no
impactonshort-termoutcome,itadverselyaﬀectslong-term
survival of both graft and patient. Most of the patients with
sustained virological response remain so after transplanta-
tion with decreased HCV-related posttransplant morbidity.
Nonresponsive HCV-positive patients or who refused inter-
feron therapymay betransplanted with optimization of their
immunosuppression because of bettersurvival than dialysis.
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